User profiles for J. Ancochea
Julio AncocheaUniversidad Autónoma de Madrid Verified email at uam.es Cited by 20348 |
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
…, JH Ryu, JJ Swigris, AU Wells, J Ancochea… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
Burden of disease attributable to second-hand smoke exposure: a systematic review
…, D Nguyen, P Starchenko, J Ancochea… - Preventive …, 2019 - Elsevier
Our aim was to provide a systematic review of studies on the burden of disease due to
second-hand smoke (SHS) exposure, reviewing methods, exposure assessment, diseases …
second-hand smoke (SHS) exposure, reviewing methods, exposure assessment, diseases …
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review
Background Interstitial lung disease (ILD) is a serious complication that represents the
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA-ILD …
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA-ILD …
Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities
…, G Sanchez, V Sobradillo, J Ancochea - Thorax, 2009 - thorax.bmj.com
Aims: This study aimed to determine the prevalence of chronic obstructive pulmonary disease
(COPD) in Spain and identify the level of undiagnosed disease and its impact on health-…
(COPD) in Spain and identify the level of undiagnosed disease and its impact on health-…
Determinants of underdiagnosis of COPD in national and international surveys
BACKGROUND COPD ranks within the top three causes of mortality in the global burden of
disease, yet it remains largely underdiagnosed. We assessed the underdiagnosis of COPD …
disease, yet it remains largely underdiagnosed. We assessed the underdiagnosis of COPD …
The impact of COVID-19 on patients with asthma
…, C Del Rio-Bermudez, J Ancochea… - European …, 2021 - Eur Respiratory Soc
Background An association between the severity of coronavirus disease 2019 (COVID-19)
and the presence of certain chronic conditions has been suggested. However, unlike …
and the presence of certain chronic conditions has been suggested. However, unlike …
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
…, C Suárez-Fernández, J Ancochea… - Journal of Allergy and …, 2021 - Elsevier
Background Patients with coronavirus disaese 2019 (COVID-19) can develop a cytokine
release syndrome that eventually leads to acute respiratory distress syndrome requiring …
release syndrome that eventually leads to acute respiratory distress syndrome requiring …
Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.
…, D Rigau, JB Soriano, J Ancochea - Archivos de …, 2017 - europepmc.org
The clinical presentation of chronic obstructive pulmonary disease (COPD) varies widely, so
treatment must be tailored according to the level of risk and phenotype. In 2012, the …
treatment must be tailored according to the level of risk and phenotype. In 2012, the …
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD
…, JL López-Campos, JB Soriano, J Ancochea - Archivos de …, 2012 - Elsevier
… Julio Ancochea has been paid to give conferences at educational events and/or for scientific
consulting and/or research by Boehringer Ingelheim, Novartis, Takeda-Nycomed, Almirall, …
consulting and/or research by Boehringer Ingelheim, Novartis, Takeda-Nycomed, Almirall, …
Prevalence and determinants of COPD in Spain: EPISCAN II
…, BG Cosío, G Sanchez, J Ancochea - Archivos de …, 2021 - Elsevier
Background Two previous national epidemiological studies, IBERPOC in 1997 and EPISCAN
in 2007, determined the COPD burden in Spain. Changes in demographics and exposure …
in 2007, determined the COPD burden in Spain. Changes in demographics and exposure …